Product Details
| Product Name:
TMDJ-035 |
CAS No.:
2681302-83-8 |
| Supply Ability:
10g |
Release date:
2025/10/27 |
Product Introduction
Bioactivity
| Name | TMDJ-035 |
| Description | TMDJ-035 is a selective inhibitor of the RyR2 (ryanodine receptor 2). It effectively suppresses abnormal calcium (Ca^2+) waves and transients in isolated cardiomyocytes derived from mice with RyR2 mutations. As such, TMDJ-035 serves as a valuable tool in research for elucidating the gating mechanisms and dynamics of the RyR2 channel [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | CalciumChannel | Calcium Channel |
| Inhibitors Related | Nisoldipine | Diltiazem hydrochloride | Levetiracetam | L-Ascorbic acid | L-Phenylalanine | D-Menthol | Ethyl cinnamate | L-Ascorbic acid sodium salt | 1-Octanol | 2-Nitrobenzoic acid | Methyl homoveratrate | Otilonium bromide |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries, 10000+ Noval Small Molecucles,16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
You may like
-
CAS:117828-61-2
$2500.00 / 100mg
-
CAS:756771-02-5
$0.00 / 1mg
-
CAS:27035-30-9
$1980.00 / 50mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$987.00/50mg |
VIP6Y
|
TargetMol Chemicals Inc.
|
2024-10-23 |